AR048832A1 - Tratamiento de soporte de enfermedades hepaticas - Google Patents

Tratamiento de soporte de enfermedades hepaticas

Info

Publication number
AR048832A1
AR048832A1 ARP050101588A ARP050101588A AR048832A1 AR 048832 A1 AR048832 A1 AR 048832A1 AR P050101588 A ARP050101588 A AR P050101588A AR P050101588 A ARP050101588 A AR P050101588A AR 048832 A1 AR048832 A1 AR 048832A1
Authority
AR
Argentina
Prior art keywords
treatment
support
hepatic diseases
blocker
diltiazem
Prior art date
Application number
ARP050101588A
Other languages
English (en)
Original Assignee
Smith Howard J & Ass Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004902151A external-priority patent/AU2004902151A0/en
Application filed by Smith Howard J & Ass Pty Ltd filed Critical Smith Howard J & Ass Pty Ltd
Publication of AR048832A1 publication Critical patent/AR048832A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion y un método para tratar un sujeto que padece una enfermedad hepática que comprende la administracion oral de una formulacion de liberacion retardada de un bloqueador de canales de calcio tal como diltiazem y tiamina, que también es un antioxidante relativamente hidrofílico, comparado con el bloqueador de los canales de calcio.
ARP050101588A 2004-04-22 2005-04-21 Tratamiento de soporte de enfermedades hepaticas AR048832A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004902151A AU2004902151A0 (en) 2004-04-22 Method of supportive treatment of liver disease
AU2004902447A AU2004902447A0 (en) 2004-05-07 Method of supportive treatment of liver disease

Publications (1)

Publication Number Publication Date
AR048832A1 true AR048832A1 (es) 2006-05-31

Family

ID=35196732

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101588A AR048832A1 (es) 2004-04-22 2005-04-21 Tratamiento de soporte de enfermedades hepaticas

Country Status (9)

Country Link
US (1) US7977326B2 (es)
EP (1) EP1755615B1 (es)
JP (1) JP5519906B2 (es)
KR (1) KR101312010B1 (es)
AR (1) AR048832A1 (es)
CA (1) CA2563058C (es)
HK (1) HK1100206A1 (es)
IL (1) IL178366A (es)
WO (1) WO2005102353A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110274755A1 (en) * 2004-04-22 2011-11-10 Smith Howard J Supportive treatment of liver disease
JP5519906B2 (ja) * 2004-04-22 2014-06-11 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー 肝臓疾患の支持療法
AP2011005681A0 (en) 2008-10-02 2011-04-30 George Zabrecky Methods and formulations for treating chronic liver disease.
WO2011044638A1 (en) * 2009-10-15 2011-04-21 Howard J. Smith & Associates Pty Ltd Method of treatment of liver disease
JP2013139391A (ja) * 2010-04-09 2013-07-18 Hokkaido Univ ウイルス感染抑制および／または感染症治療剤
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
FR3033701B1 (fr) * 2015-03-19 2021-01-15 Univ Claude Bernard Lyon Nouvelles compositions antivirales pour le traitement de la grippe
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
FR3081325B1 (fr) * 2018-05-23 2020-10-09 Univ Claude Bernard Lyon Diltiazem pour son utilisation dans le traitement des infections microbiennes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US452555A (en) * 1891-05-19 Ice-pick
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US4917899A (en) 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
IE56999B1 (en) 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5002776A (en) 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
US5219621A (en) 1987-10-16 1993-06-15 Elan Corporation, Plc Methods of treatment with diltiazem formulations
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
DE19515971A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Kombinationspräparate mit vaskulärer Wirkung
US20030049840A1 (en) * 1998-10-07 2003-03-13 Demetriou Achilles A. Cell preconditioning and cryopreservation medium
JP3923793B2 (ja) * 2001-11-30 2007-06-06 大日本印刷株式会社 画像形成方法及び画像形成物
EP1340622B1 (en) * 2002-03-01 2006-12-13 Dai Nippon Printing Co., Ltd. Thermally transferable image protective sheet, method for protective layer formation, and record produced by said method
JP5519906B2 (ja) * 2004-04-22 2014-06-11 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー 肝臓疾患の支持療法

Also Published As

Publication number Publication date
CA2563058A1 (en) 2005-11-03
IL178366A0 (en) 2007-02-11
US20070292507A1 (en) 2007-12-20
HK1100206A1 (en) 2007-09-14
IL178366A (en) 2014-01-30
EP1755615B1 (en) 2013-11-27
CA2563058C (en) 2012-10-16
EP1755615A4 (en) 2009-07-29
KR20070014185A (ko) 2007-01-31
KR101312010B1 (ko) 2013-09-30
JP2007533667A (ja) 2007-11-22
EP1755615A1 (en) 2007-02-28
JP5519906B2 (ja) 2014-06-11
US7977326B2 (en) 2011-07-12
WO2005102353A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
AR048832A1 (es) Tratamiento de soporte de enfermedades hepaticas
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
ECSP17046065A (es) Formas cristalinas de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolhidrocloruro (solicitud divisional)
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
GT200500127A (es) Composiciones y metodos para el tratamiento de trastorno disforico premenstrual
HK1156515A1 (en) Pharmaceutical compositions and methods for accelerating wound healing
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
AR012264A1 (es) Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
AR043987A1 (es) Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
AR109263A2 (es) Composición que comprende moxidectina
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
GT200500102A (es) Compuestos de aril-o-heteroarilamida ortosustituidos
DOP2006000252A (es) Profarmacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y metodos
ECSP066392A (es)
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
ECSP11011151A (es) Compuestos purina
MXPA05014166A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
UY29320A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, así como preparaciones farmacéuticas que las contienen
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
AR056500A1 (es) Metodo para preparar una composicion medica

Legal Events

Date Code Title Description
FB Suspension of granting procedure